EBR Systems Refocused United States Sales Strategy
The company adjusted its commercial approach in the third quarter of 2026 after a leadership transition.
Updated on Oct. 12, 2026 in Healthcare
Live Poll
Is focusing on existing patient care better for long-term health outcomes than rapid facility expansion?
EBR Systems refocused its United States sales strategy during the third quarter of 2026 following changes in commercial leadership. The company reported 40 commercial WiSE implants during the period, bringing the total number of implants to 157.
Why it matters
Quarterly implant volumes declined as the company managed leadership transitions and shifted focus toward deeper utilization of existing hospital accounts. CEO John McCutcheon is currently overseeing the commercial organization while recruiting a permanent leader.
EBR Systems signed five new purchasing contracts in Q3 2026 and expects revenue for the quarter to fall between $2.43 million and $2.53 million. The facility in Santa Clara achieved ISO 13485 certification and holds a potential annual revenue capacity of approximately $607.6 million.
The players
EBR Systems
This medical technology company specializes in developing the WiSE system for cardiac pacing.
John McCutcheon
He is the CEO of EBR Systems and is currently managing commercial operations on an interim basis.
The details
The company is prioritizing physician training and increased procedure frequency, with 100 physicians now certified to perform WiSE system implants. Additionally, the Santa Clara manufacturing site recently underwent an FDA pre-approval inspection.
Timeline
EBR completed a $150 million capital raise in August 2026.
By September 30, 2026, the company had activated 40 hospital accounts.
Increased Medicare inpatient reimbursement rates took effect on October 1, 2026.
EBR anticipates FDA approval of its new manufacturing site by the end of 2026.
Market Landscape
EBR Systems is aligning its commercial deployment with the Centers for Medicare & Medicaid Services inpatient prospective payment system to bolster revenue. This strategic shift follows the expansion of their manufacturing capabilities in Santa Clara.
Patients may see increased access to WiSE procedures as more physicians receive training and hospital accounts become activated. The recent Medicare reimbursement updates may also reduce financial barriers for eligible patients seeking these specialized treatments.
The takeaway
The company is focusing on internal training and operational scaling to stabilize its commercial performance. Investors and patients should watch for the anticipated FDA site approval by the end of 2026 to gauge future supply capacity.
Further reading
For more on industry developments, see Healthcare.
Live Poll
Is focusing on existing patient care better for long-term health outcomes than rapid facility expansion?
